| Zhang, Yi |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 03/24 | 03/24 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 71 | RoW | TQ-B3139 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/22 | 10/22 | | |
NCT03638206: Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies |
|
|
| Recruiting | 1/2 | 73 | RoW | CAR-T cell immunotherapy | Shenzhen BinDeBio Ltd., The First Affiliated Hospital of Zhengzhou University | B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma, Hepatoma, Gastric Cancer, Pancreatic Cancer, Mesothelioma, Colorectal Cancer, Esophagus Cancer, Lung Cancer, Glioma, Melanoma, Synovial Sarcoma, Ovarian Cancer, Renal Carcinoma | 03/23 | 03/23 | | |
NCT05117138: Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors |
|
|
| Not yet recruiting | 1/2 | 39 | RoW | AMT-116 CAR-T cells, AMT-253 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Melanoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 12/23 | 03/24 | | |
NCT06316791: Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases |
|
|
| Recruiting | 1 | 24 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Lupus Erythematosus, Systemic | 12/24 | 12/25 | | |
NCT05122221: CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers |
|
|
| Recruiting | 1 | 12 | RoW | Fludarabine + Cyclophosphamide, Interleukin-2, CRTE7A2-01 TCR-T Cell | Corregene Biotechnology Co., Ltd | Cervical Cancer, Anal Cancer, Head and Neck Cancers | 03/23 | 12/24 | | |
NCT06152757: BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors |
|
|
| Recruiting | 1 | 14 | RoW | First dose, Second dose, The third dose, The fourth dose | BioSyngen Pte Ltd, The First Affiliated Hospital of Zhengzhou University | Gastrointestinal Tumors | 07/25 | 07/27 | | |
NCT05381181: Safety and Efficacy Evaluation of Next-generation CD19-UCART |
|
|
| Not yet recruiting | 1 | 20 | NA | CD19-UCART | Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University | Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | 05/24 | 05/26 | | |
NCT06077903: GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | GT101 | Grit Biotechnology | Adult | 07/24 | 07/24 | | |
NCT06548620: A Study of RD06-04 in Patients With Active Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 18 | RoW | RD06-04 cell infusion | Nanjing Bioheng Biotech Co., Ltd. | SLE (Systemic Lupus), Sclerosis, ANCA Associated Vasculitis, IIM, SS, MS, NMO Spectrum Disorder, MG | 08/26 | 08/27 | | |
NCT06094426: Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | GT316 | Grit Biotechnology | Solid Tumor, Adult, GT316 | 02/26 | 02/26 | | |
NCT03908671: Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 24 | RoW | Personalized mRNA Tumor Vaccine | Stemirna Therapeutics, The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer, Non Small Cell Lung Cancer | 10/24 | 12/25 | | |
NCT06658951: Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors |
|
|
| Not yet recruiting | N/A | 30 | RoW | Anti-HER2 CAR-T cells | UTC Therapeutics Inc., The First Affiliated Hospital of Zhengzhou University | HER2-positive Advanced Malignant Solid Tumors | 11/26 | 11/27 | | |
NCT05308875: Efficacy and Safety Evaluation of PD1-BCMA-CART |
|
|
| Not yet recruiting | N/A | 9 | RoW | PD1-BCMA-CART | Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University | Multiple Myeloma | 01/25 | 10/25 | | |
| Recruiting | N/A | 1000 | US | MicroVention Mechanical Thrombectomy Devices as first-line treatment | Microvention-Terumo, Inc. | Acute Ischemic Stroke, Vessel Occlusion, Stroke, Ischemic | 12/25 | 12/25 | | |
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study |
|
|
| Recruiting | N/A | 154 | US | FRED™ X™, Flow Re-Direction Endoluminal Device X | Microvention-Terumo, Inc. | Intracranial Aneurysm | 09/29 | 11/29 | | |
